Our internet site may contain information that is not approved in all countries or regions. To ensure accuracy of content, please select your country/region of residence. Choose International if your country is not listed.
This information will be saved using cookies. To find out more about cookies, read our Privacy Policy.
Please select your country of residence. Choose International if your country is not listed.
Our internet site may contain information that is not approved in all countries or regions. To ensure accuracy of content, it is required that you select the site which is appropriate for your country of residence.
MetaSystems Probes has already certified a large part of its portfolio, according to IVDR. For organizational reasons, we currently provide only the IVDD product.
Discover all IVDR-certified products
XL 5p15/21q22 consists of a green-labeled probe hybridizing to a region at 5p15.2-15.3 and an orange-labeled probe hybridizing to the DSCR4 gene region at 21q22.1-22.2.
Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.
Multiple myeloma (MM) is a malignant disorder of plasma cells representing the second most prevalent hematologic malignancy, which is characterized by a wide heterogeneity of disease progression. While some of the MM patients stay alive more than 10 years after first diagnosis, others die within a few months. Chromosomal abnormalities in tumor plasma cells are of great significance among all prognostic factors analyzed in MM. To address the significant role of the different factors, the International Myeloma Working Group has recommended the implementation of these well studied chromosomal aberrations in the revised International Staging System (R-ISS) for MM. While del(17p), t(4;14), and t(14;16) are known to be among the high-risk factors in MM, trisomic MM is generally associated with a favorable outcome. More than half of MM cases diagnosed have a hyperdiploid karyotype, characterized by gains of the odd chromosomes.
While trisomy 3 or 5 significantly improves overall survival in MM patients, trisomy 21 has the adverse effect. The study of Perrot et al analyzed the combination frequency and prognostic impact of the factors del(17p), t(4;14), del(1p32), 1q21 gain, and trisomies 3, 5, and 21 within a big cohort and found out that the most frequent combination was the one between trisomy 5 and 21 among the aberrations examined.
The combined XL 5p15/21q22 fluorescence in situ hybridization (FISH) probe is a helpful aid for diagnosis to rapidly detect trisomy 5 and, or 21 in suspected or confirmed MM cases.
XL 5p15/21q22 hybridized to lymphocytes. One normal interphase and one normal metaphase are shown.
Normal Cell:
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
Three green (3G) and two orange (2O) signals resulting from gain of one green signal.
Aberrant Cell (typical results):
Two green (2G) and three orange (3O) signals resulting from gain of one orange signal.
Aberrant Cell (typical results):
Three green (3G) and three orange (3O) signals each resulting from a gain of one green signal and one orange signal.
Certificate of Analysis (CoA)
or go to CoA DatabaseMetaSystems Probes has received IVDR certification for our initial 26 fluorescence in situ hybridization (FISH) probes from the notified body, BSI. Achieving this milestone was not without its challenges, and we are delighted to have accomplished IVDR certification for this probe set at an early stage.
We hope you had a chance to meet us.
The IVDR is effective and our probes stay the same! A large segment of our portfolio is already IVDR-certified. Our priority is to give you a smooth transition into the IVDR era.
